New sequences in higher lines of treatment of clear cell carcinoma of the kidney

03/2018

Prof. MUDr. Jindřich Fínek, Ph.D., MHA

Onkologická a radioterapeutická klinika LF UK a FN, Plzeň

 

SUMMARY

Two new molecules, nivolumab (anti-PD-1) and cabozantinib (a multikinase inhibitor of the VEGF, AXL and MET pathway), are coming into the treatment of metastatic clear cell carcinoma of the kidneys. In the second treatment line, both offer an identical survival extension of five months compared to everolimus. Cabozantinib appears to be more appropriate in patients with bone metastases and when rapid onset of action is required. In contrast, nivolumab has an advantage in patients with high tumor burden.

 

KEYWORDS

light cell carcinoma of the kidney, nivolumab, cabozantitib

 

 

Celý článek je dostupný pouze pro předplatitele

Staňte se pravidelným odběratelem našeho časopisu Onkologická revue...

 

VÍCE O PŘEDPLATNÉM